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Vaccination remains a major tool for prevention and progression of Johne’s disease, a
chronic enteritis of ruminants worldwide. Currently there is only one licensed vaccine
within the United States and two vaccines licensed internationally against Johne’s
disease. All licensed vaccines reduce fecal shedding of Mycobacterium avium subsp.
paratuberculosis (MAP) and delay disease progression. However, there are no available
vaccines that prevent disease onset. A joint effort by the Johne’s Disease Integrated
Program (JDIP), a USDA-funded consortium, and USDA—APHIS/VS sought to identify
transposon insertion mutant strains as vaccine candidates in part of a three phase study.
The focus of the Phase I study was to evaluate MAP mutant attenuation in a well-defined
in vitro bovine monocyte-derived macrophage (MDM) model. Attenuation was determined
by colony forming unit (CFUs) counts and slope estimates. Based on CFU counts alone,
the MDM model did not identify any mutant that significantly differed from the wild-type
control, MAP K-10. Slope estimates using mixed models approach identified six mutants
as being attenuated. These were enrolled in protection studies involving murine and baby
goat vaccination-challenge models. MDM based approach identified trends in attenuation
but this did not correlate with protection in a natural host model. These results suggest
the need for alternative strategies for Johne’s disease vaccine candidate screening and
evaluation.
Keywords: Mycobacterium avium subsp. paratuberculosis, Johne’s disease, vaccine, macrophage, mutant,
transposon mutagenesis, survival
INTRODUCTION
Vaccination is arguably the most successful story in medical
research that has improved the longevity and quality of life for
both humans and animals (Koff et al., 2013). Currently there
is one licensed vaccine for Johne’s disease, a chronic enteri-
tis of ruminants worldwide caused by Mycobacterium avium
subsp. paratuberculosis (MAP), within the United States (Patton,
2011). Mycopar (Boehringer, Ingelheim, Ridgefield, CT, USA) is
a heat-killed bacterin of Mycobacterium avium mixed with an
oil adjuvant. Other vaccine formulations available internationally,
Gudair (Zoetis, Inc.) and Silirum (Pfizer), are composed of heat
inactivated MAP strain 316F (for use in ovine paratuberculosis)
and a heat killed strain of MAP (for use in bovine paratuberculo-
sis), respectively (Reddacliff et al., 2006; Stringer et al., 2013). All
licensed vaccines reduce fecal shedding of MAP but fail to pro-
duce protection from initial infection and sterilizing immunity in
ruminants (Chiodini, 1993; Reddacliff et al., 2006; Rosseels and
Huygen, 2008; Huttner et al., 2012) Furthermore, these vaccine
formulations frequently result in granulomas and/or lesions at the
site of injection as well as antibody responses that cross-react with
other pathogenic mycobacteria, and does not reliably differentiate
vaccinated from infected animals, creating difficulties in disease
detection (Mackintosh et al., 2005; Eppleston andWindsor, 2007;
Stabel et al., 2011; Thomsen et al., 2012; Hines et al., 2014). Due
to undesirable consequences of vaccination, which includes injec-
tion site reactions and inference with TB diagnostics, the United
States limits Mycopar to herds that have a high MAP prevalence
or those that have limited resources (financial, facility, etc.) to
achieve Johne’s disease control program standards (Usda-Aphis,
2010).
Despite the risk of potential immunization sequelae, several
studies indicate that vaccination is a necessary component for
Johne’s disease prevention (Kormendy, 1994; Lu et al., 2013). In a
stochastic simulation model of MAP infection and vaccination,
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Lu et al. showed that effective vaccination of animals reduced
MAP prevalence to 0.44 and 0.19 at a 5 and 10 year follow-
up period, respectively (Lu et al., 2013). It is important to note
that the authors also concluded that a small chance (<0.15) of
MAP persistence due to vertical transmission exists (Lu et al.,
2013). Therefore, it is likely that Johne’s disease eradication must
encompass vaccination under the umbrella of a well-defined con-
trol program that includes standard management practices for
rapid detection, hygiene, separation of newborns from adults, and
culling of infected animals (Ferrouillet et al., 2009; Espejo et al.,
2012).
The need for an improved Johne’s disease vaccine within
management programs prompted the implementation of a three-
phase vaccine candidate evaluation that was administered by the
Johne’s Disease Integrated Program (JDIP). This vaccine project
consisted of three blinded studies: Phase I involved the screen-
ing of 22 submitted strains of MAP, carrying deletions at criti-
cal housekeeping or putative virulence genes (herein collectively
referred to as MAP mutants), for attenuation in a well-defined
bovine monocyte-derived macrophage (MDM) model, Phase II
involved identified attenuated mutants from Phase I evaluation
in a mouse vaccination-challenge model, and Phase III involved
the evaluation of selected mutants from Phase II in a goat chal-
lenge model to evaluate protection in a ruminant host, which is
the target species. We herein report results from the Phase I study.
Mutant MAP strains classified as candidates for further testing
were defined as those displaying significant attenuation, particu-
larly based on slope trends indicative of total bacterial decay over
the first 48-h post infection.
MATERIALS AND METHODS
ETHICS STATEMENT
All animal work was conducted in accordance with the recom-
mendations in the institutional guidelines and approved animal
care and use committee (IACUC) protocols at the University
of Minnesota (approval number 1106A01161). All other exper-
iments were carried out in accordance with the University of
Minnesota’s Institutional Biosafety Committee (IBC) approved
protocol number 0806H36901.
STUDY DESIGN
All experiments were conducted in a double-blind design. The
attenuated mutant strains were cultured, coded, and shipped to
the testing labs by the coordinating team at Penn State University.
At the end of the study, the MDM survival data of strains was
decoded and analyzed by the JDIP Statistical Core at Cornell
University.
PURIFICATION OF BOVINE MONOCYTE-DERIVED MACROPHAGES
(MDMs)
Purification of bovine MDMs was conducted using a published
protocol (Janagama et al., 2006). Briefly, whole blood was col-
lected from the jugular vein into gas sterilized vacuum buckets
containing ACD or CPDA anticoagulant. The blood was cen-
trifuged at 2000 × g for 20min at room temperature (RT) and
buffy coats were harvested and diluted 1:10 in PBS before separa-
tion over a 58% percol gradient. After centrifugation of the percol
gradient at 400 × g for 30min at RT, the mononuclear cells were
collected using a sterile transfer pipette into a 20-ml new tube.
Three PBS washes were performed on cells to remove remaining
percol. After the last PBS wash, the cell pellet was resuspended in
RPMI 1640 medium (Gibco, Invitrogen, Carlsbad, CA) with 20%
autologous serum in Teflon wells. Cell suspensions were incu-
bated inside a humidified chamber containing 5% CO2 at 37◦C
and allowed to differentiate for 4 days before they were seeded
only cell culture flasks (day 5). Cell culture medium was changed
every 2–3 days.
BACTERIAL CELL CULTURE
MAP mutant strains submitted by multiple investigators were
received at Pennsylvania State University and cultured in
Middlebrook (MB) 7H9 supplemented with 10% glycerol, 1%
oleic acid-dextrose-catalase (OADC) or ADC, 0.05% Tween-
80, cycloheximide (1.0 g/L), mycobactin J (2mg/mL) (Allied
Monitor, and appropriate antibiotics at 37◦C at 120 rpm. Growth
was determined on a weekly basis by recording culture absorbance
(O.D.600 nm) after several passages through G25 and G27 nee-
dles. Upon reaching an O.D.600 nm of 0.5, cultures were tested
for contamination by the absence of both growth on Brain-
Heart Infusion (BHI) and blood agar for 48 h and M. avium
specific PCR not present in MAP (primer sequences: F 5′-
aaacccaagcagagaaacga; R 5′-gcgtcaatcaaagcctgttc). MAP mutant
strains were blinded and shipped to testing laboratories, then
used to infect MDMs immediately upon receipt. Colony counts
were determined after shipment by plating serial dilutions (10−4
through 10−7) of each culture (in triplicate) on MB7H9 agar
plates and incubating for 4–6 weeks. Baseline CFUs were calcu-
lated based on averages obtained from triplicate plates of 10−5
and 10−6 dilutions.
MAP INVASION ASSAY
Unless stated otherwise, all incubations were conducted in a 37◦C
humidified chamber containing 5% CO2. Bovine MDMs were
counted via trypan blue exclusion, seeded at 2.0 × 106 cells in T-
25 culture flasks, and allowed to adhere for 2 h in the humidified
chamber (5% CO2 at 37◦C). Non-adherent cells were removed by
washing flasks three times in 1× PBS. RPMI 1640 supplemented
with 2% autologous serum (infection medium) was added to
each flask prior to MAP invasion. MAP cultures were pelleted at
8000× g for 10min, washed thrice using 1× PBS, resuspended in
infection medium (MOI 10:1), and vortex mixed for 5min. MAP
cells were repeatedly drawn through a 21-gauge needle to disso-
ciate bacterial clumps. Cells were incubated at 37◦C for 5min to
sediment any remaining clumps and only the upper 2/3 volume
was used for the invasion assay. MDMs were infected with MAP
for 2 h, washed thrice with 1× D-PBS to remove non-adherent
bacteria, and recovered in fresh infection medium for the fol-
lowing time points: 3, 24, 48, 96, and 168 h. Time points were
selected upon well-established steps in MAP invasion, gene and
protein expression, and adaptation to the intracellular environ-
ment (Murphy et al., 2006; Scandurra et al., 2009, 2010; Lamont
and Sreevatsan, 2010; Ghosh et al., 2013). Upon completion of
time points, MDMs were washed thrice in 1× D-PBS and incu-
bated with warmed 0.01% Triton X-100 in PBS for 5min at RT.
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The lysate was subjected to differential centrifugation at 388 × g
and 8000 × g for 5min each to remove MDMs and pellet MAP,
respectively. MAP pellets were washed thrice in 1× PBS at 8000×
g for 5min to remove any remaining detergent, and resuspended
in 1.0mL of 1× PBS. All time points were conducted in trip-
licate. During the infection time course, medium was replaced
every 2 days. Recovered MAP cells were serially diluted in 1×
PBS and plated on MB7H9 agar supplemented with 10% OADC,
mycobactin J (2 mg/mL), and appropriate antibiotics (kanamycin
or hygromycin). All plates were incubated at 37◦C for 6–8 weeks.
IS900 colony PCR was performed on randomly selected colonies
from each dilution to confirm purity as described (Bull et al.,
2000). All dilutions were plated in duplicate.
STATISTICAL ANALYSIS PERFORMED BY THE UNIVERSITY OF
MINNESOTA
CFU numbers fromMAPmutant strains were normalized against
the MAP K-10 starting inoculum in order to achieve direct com-
parisons at each post infection time point. Results were plotted
and analyzed using One-Way analysis of variance (ANOVA) with
Bonferroni correction in GraphPad Prism software (GraphPad
Software, La Jolla, CA). P values of less than 0.05 were consid-
ered as statistically significant. Analysis is reflective of CFU counts
from the University of Minnesota.
STATISTICAL ANALYSIS PERFORMED BY JDIP CORE
CFU numbers were submitted to the JDIP core. CFUs in bovine
MDMs measured from different time points and the change (i.e.,
slope) between 3 and 48 h was calculated to compare mutants,
as follows. CFU measurements were not normalized to the stan-
dard type inoculum. The natural logarithm was applied to mean
CFUs/mL (calculated for each time point, cow and strain). Slope
estimates were calculated by subtracting the (natural logarithm
of the mean CFU/ml count at 3 h) from the (natural logarithm of
the mean CFU/ml count at 48 h) and dividing by 45 (=48–3).
Sixty-nine observations (one for each combination of univer-
sity, strain and cow) were recorded and analyzed using PROC
GLIMMIX ver. 9.2 in SAS (SAS Institute Inc., Cary, NC) using
a linear regression model. The outcome variable was the slope
estimate described above. These slope estimates were assumed
to follow a normal distribution. The independent variable strain
was a fixed effect, with 17 levels. University was a random
effect with 2 levels. Final analysis included observations recorded
from both the University of Minnesota and the University
of Wisconsin-Madison.
RESULTS
MAP MUTANT COMPETENCE IN AN IN VITRO PRIMARY
MONOCYTE-DERIVED MACROPHAGE MODEL
Survival of MAP mutants was performed in two stages. First, a
direct comparison of all mutants against K-10 was performed.
Second, a slope trend was determined using a mixed linear
model approach. Table 1 lists mutant identification, transposon
insertion location and method. Survival of MAP mutants was
determined at 3, 24, 48, 96, and 168 h p.i. in a well-defined
bovine MDMmodel (Figure 1). Due to varying CFUs in bacterial
inoculums, all strains were normalized to MAP K-10 inoculum.
All MAP strains, including MAP K-10, showed similar CFU
counts throughout the course of the study (Figure 1). Statistical
analysis of mutant CFU results compared to MAP K-10 showed
no significant (P > 0.05) differences at any time point.
In as much as, direct comparisons over the entire infection
cycle did not capture differences, a mixed model approach was
applied to identify slope trends between strains. Attenuation
was determined by slope-value for each MAP strain (Table 1).
Mutants that showed a negative slope were identified as attenu-
ated in the MDMmodel. MAPmutant strains selected to proceed
to Phase II studies were required to either show a decaying trend
(i.e., negative slope-estimate) or induced apoptosis in PBMCs
as described (Kabara and Coussens, 2012). Mutant strains 312–
314 and 322–326 showed positive slopes; therefore, these mutants
were excluded from the Phase II study (Table 1). Mutant strains
315, 316, 318, 319, and 321 showed negative slopes ranging
from −0.0265 to −0.018 (Table 1). The inclusion of strains 320
and 329 (referred to asMutant 219 in Kabara and Coussens, 2012)
were based on apoptosis collected from another JDIP core labora-
tory (Kabara and Coussens, 2012). Based on these analyses, JDIP
315–321 and 329 were selected for further evaluation in Phase II
studies.
DISCUSSION
Johne’s disease vaccination was first described in 1926 using a live
strain of MAP mixed with olive oil, paraffin, and pumice powder
as an adjuvant (Valle and Rinjard, 1926). Johne’s disease vac-
cine strategies have expanded and diversified due to the public
availability of the MAP genome and gene regulation studies (Li
et al., 2005; Bannantine and Talaat, 2010; Janagama et al., 2010;
Chen et al., 2012). Currently, potential vaccine models for Johne’s
disease include heat-killed bacilli, live attenuatedmutants, recom-
binant MAP proteins, and MAP genes integrated into viruses or
unrelated bacterial plasmids (Cavaignac et al., 2000; Rosseels and
Huygen, 2008; Faisal et al., 2013). However, the only licensed
Johne’s disease vaccine within the United States, Mycopar–
comprised of heat-killed M. avium (erroneously labeled as MAP
in the literature prior to 1993), and other heat-killed formulations
do not provide protection against infection and is fraught with
negative immunization sequelae (Chiodini, 1993; Ghadiali et al.,
2004; Eppleston and Windsor, 2007; Paustian et al., 2008; Patton,
2011; Stringer et al., 2013). The use of Mycopar is restricted to
herds with high MAP prevalence in order to reduce MAP shed-
ding and/or delay disease onset (Usda-Aphis, 2010). In order to
achieve Johne’s disease eradication it is critical that a vaccine that
elicits protection be included with strong, standardized manage-
ment protocols. In a series of three studies (Phase I–III), MAP
mutants submitted to JDIP were evaluated for vaccine candidacy.
This study (Phase I) evaluated MAP mutant attenuation in an
in vitroMDMmodel.
Screening of MAP mutants against strain K-10 was conducted
in a well-defined in vitro bovine MDM model to define attenua-
tion. Previous studies have shown that bovine MDMs serve as an
efficient mechanism for rapid analysis of potential vaccine candi-
dates (Langelaar et al., 2005; Scandurra et al., 2009, 2010). CFU
data were first analyzed for the full 7-day period in an attempt
to identify trends in attenuation. Since most drop in CFUs were
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Table 1 | MAP mutant identification, strain information, and slope estimates.
JDIP core Strain information Slope estimatea
identification Name Background Location Method
311 482-3 43432-02 (Goat) MAP0482 and MAP0483 Site directed deletion
(McGarvey, unpublished)
−0.0421
312 K10-relA K-10 (Cattle) relA/deletion of the region
between 732th bp and 1604th bp
of the gene
Phage/site directed (Park
et al., 2008)
0.0270
313 K10-pknG K-10 pknG/deletion of the region
between 406th bp and 2142th bp
of the gene
0.0294
314 K10-lrs2 K-10 lsr2/deletion of the region
between 9th bp and 319th bp of
the gene
0.0336
315 STM68 (GPM401) K-10 Internal to MAP1566, insertion is
located near the 3’ end
Transposon mutagenesis;
phAE94 to introduce Tn5370
(Liveneh et al., 2005)
−0.0265
316 2E11 (GPM402) K-10 Intergenic, 137 bp upstream from
fadE5, between MAP3695 and
FadE5
Transposon mutagenesis;
phAE94 to introduce Tn5367
(Liveneh et al., 2005)
−0.0211
317 22F4 (GPM403) K-10 Internal to lsr2 (MAP0460) 0.0003
318 40A9 (GPM404) K-10 Intergenic, between MAP0282c
and MAP0283c
−0.018
319 30H9 (GPM405) K-10 Internal to MAP1566 −0.0146
320 3H4 (GPM406) K-10 Intergenic, between MAP2296c
and MAP2297c
0.0186
321 4H2 (GPM407) K-10 Intergenic between MAP1150c
and MAP1151c
−0.0130
322 WAg906 (TM58) 989 (C strain; Type II) MAP1566 Transposon mutagenesis
(Tn5367) (Cavaignac et al.,
2000)
0.0038
323 WAg915 K-10 ppiA (MAP0011) inactivated by
allelic exchange
Site directed mutagenesis
using a phage vector
0.0236
324 kdpC ATCC 19698 MAP0997c kdpC Transposon mutagenesis
(Tn5367) (Shin et al., 2006)
−0.0025
325 lipN K-10 lipN Homologous recombination
(Wu et al., 2007)
0.0043
326 umaA1 ATCC 19698 MAP3963 umaA1 Transposon mutagenesis
(Tn5367) (Shin et al., 2006)
−0.0284
329 fabG2_2 ATCC 19698 MAP2408c fabG2_2 Transposon mutagenesis (Tn
5367) (Wu et al., 2007)
0.0198
aSlope-estimates based-off of data recorded from the University of Minnesota and the University of Wisconsin-Madison.
restricted to an earlier infection time point a slope based approach
was applied where each mutant was compared against others
for 48-h post infection. Mutants with highest slopes (indicat-
ing higher rates of intracellular incompetence) were selected as
likely attenuated strains for further screening in a mouse model
for immunogenicity. While slope values and percent cell apop-
tosis predicted attenuation, it did not correlate with protection
as determined by the results of Phase II and Phase III studies
(Bannantine et al., 2014; Hines et al., 2014). For example, in
Phase II trialsMAPmutants 316–318 showed the highest bacterial
burden in cultured tissues (spleen and liver) (Bannantine et al.,
2014). Although MAP strain 315 outperformed all other mutants
tested in the murine model, the undiluted Silirum vaccine offered
the greatest protection as determined by decreased counts of
bacterial burden in tissues (Bannantine et al., 2014). Poor pro-
tection against standard type infection using MAPmutant strains
were also demonstrated in a goat challenge model (Hines et al.,
2014). The MAP mutant strain 329 performed the best in the
goat model as it reduced bacterial shedding, lowered bacterial
burden, and decreased tissue lesion scores (Hines et al., 2014).
However, like the murine study, strain 329 failed to outperform
the Silirum vaccine. Together these data highlight the limita-
tions of overextending the bovine MDM attenuation model as
a proficient tool for initial screening of MAP mutants to pre-
dict vaccine candidacy i.e., immunogenicity or ability to prevent
infection.
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FIGURE 1 | Survival of MAP mutants in a primary cell in vitro bovine
MDM model. All MAP mutant inoculums were normalized to that from
MAP strain K-10. Bovine MDMs were incubated at 3, 24, 48, 96, and 168 h.
and subsequently lysed for MAP CFU culture. MAP mutant CFU counts did
not differ significantly from the control, MAP strain K-10. Error bars
represents standard error from the mean (s.e.m). Experiment represents
data from 2 cows from the University of Minnesota. All time points were
conducted in triplicate. n.s. is abbreviated for not significant. Gray line
separates inoculum from the infection time points.
Although traditional vaccine strategies largely rely on
attenuation either by heat inactivation or mutation, this strat-
egy appears to be unsuccessful for mycobacteria. For example,
Mycobacterium BCG, the only licensed vaccine against human
tuberculosis (TB), contains multiple deletions but has variable
efficacy in adults and fails to protect against pulmonary TB
(Behr, 2002; Lewis et al., 2003; Kaufmann, 2013). Current vac-
cine designs for TB include improvements upon BCG by the
addition of foreign genes, such as listeriolysin, that forces the
pathogen to be presented to the immune system via an unnatu-
ral mechanism (Grode et al., 2005). It is likely that Johne’s disease
vaccines will need to utilize similar strategies to elicit immunity.
Promising Johne’s disease vaccine candidates utilizing unconven-
tional methods include those that present MAP antigens in a
Salmonella backbone, recombinant MAP proteins and DNA con-
structs (Kadam et al., 2009; Santema et al., 2009, 2011; Chandra
et al., 2012; Faisal et al., 2013).
Despite limitations in theMDMmodel to predict good vaccine
candidates instead of simply measuring attenuation, screened
MAP mutants may direct future design of vaccines. For instance,
MAP mutants will provide critical clues as to how MAP is pro-
cessed by the immune system. Host and MAP mutant transcrip-
tomes will provide information pertaining to conserved pathways
that should be considered during vaccine design (Lamont et al.,
2013).
CONCLUSIONS
Phase I showed that attenuation of in-vitro growth rates in MDM
do not correlate with ability to prevent infection in a relevant
animal model of infection. These results highlight one of the
limitations of the widely used bovine MDM model for vac-
cine candidate identification based on an attenuation phenotype
alone. Future studies should consider alternate vaccine candi-
date screens and include multiple readouts including—antigen
processing and presentation, efficiency of modulating subcellular
processing events and ability of vaccine candidates to induce
specific cytokines, in addition to the survival trait.
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